Search clinical trials for: hypoxia-inducible factor propyl-hydroxylase inhibitor

Total 88922 results

Alexandria University

Recruiting

Effect of Low Doses of Hypoxia-inducible Factor- Prolyl Hydroxylase Enzyme Inhibitor Plus Iron in the Treatment of Anemia in Dialysis-dependent Chronic Kidney Disease Patients

Anemia in Dialysis-dependent CKD Patients

Egypt
Akebia Therapeutics

Suspended

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents (CORRECTION)

Anemia of Chronic Kidney Disease

United States
Akebia Therapeutics

Suspended

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease (CONVERSION)

Anemia of Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Anemia | Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

Anemia | End Stage Renal Disease

United States
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Canada, Korea, Republic of, United Kingdom, Australia, Germany, Israel, France, Portugal, Bulgaria, Russian Federation, Ukraine, Poland, Brazil, Argentina, Mexico, Serbia
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Anemia | Non-Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Spain, Czechia, Korea, Republic of, Malaysia, Australia, New Zealand, United Kingdom, Germany, Turkey, Ukraine, France, Hungary, Austria, Israel, Bulgaria, Russian Federation, Romania, Slovakia, South Africa, Canad... and more
Akebia Therapeutics

Completed

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

Anemia | Non-Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Korea, Republic of, Australia, New Zealand, South Africa, United Kingdom, Spain, Ukraine, Hungary, Israel, Bulgaria, Russian Federation, Mexico, Poland, Brazil, Argentina, Malaysia, Puerto Rico, France
Akebia Therapeutics

Completed

Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis Dependent Chronic Kidney Disease

Japan
Akebia Therapeutics

Completed

Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)

Anemia | Non-dialysis Dependent Chronic Kidney Disease

Japan
Akebia Therapeutics

Terminated

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy Adults

Healthy

United States
Akebia Therapeutics

Withdrawn

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (TRILOGY)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML

Refractory Acute Myeloid Leukemia | Conditioning | Hematopoietic Stem Cell Transplantation | Relapse Leukemia
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

RC48 Combined With Adebrelimab and Apatinib and S-1 of the Neoadjuvant Therapy of Locally Advanced Gastric Cancer

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Insel Gruppe AG, University Hospital Bern

Recruiting

Predicting Outcomes in ICH Patients on Direct Factor Xa Inhibitors (FIRE-Xa)

Intra Cerebral Hemorrhage

Switzerland
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

Efficacy and Safety
M.D. Anderson Cancer Center

Not yet recruiting

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

Myeloid Malignancies | Lymphodepleting Chemotherapy

United States
Children's Hospital of Fudan University

Not yet recruiting

Thalidomide Therapy for VEOIBD

Inflammatory Bowel Diseases
MedSIR
Stemline Therapeutics, Inc.

Not yet recruiting

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (ADELA)

Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | ESR1 Gene Mutation
Mayo Clinic
National Cancer Institute (NCI)

Not yet recruiting

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Unresectable Pancreatic Adenocarcinoma

United States
University of Salerno

Not yet recruiting

Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients (BESAFE)

Cardiovascular Diseases | Dyslipidemias | Lipid Metabolism Disorders | Statin Adverse Reaction
Mayo Clinic

Not yet recruiting

Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (DIVINE)

Recurrent Prostate Cancer | Castration-resistant Prostate Cancer | Stage IVB Prostate Cancer AJCC v8 | Recurrent Castration-Sensitive Prostate Carcinoma

United States
Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC
Masonic Cancer Center, University of Minnesota

Not yet recruiting

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Autologous Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Seagen Inc.

Recruiting

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Hodgkin Lymphoma

United States
University Health Network, Toronto

Not yet recruiting

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

Melanoma (Skin)

Canada
Nanjing University School of Medicine

Recruiting

Daratumumab for Patients With Light Chain Amyloidosis

Light Chain (AL) Amyloidosis

China
Shen Lei

Not yet recruiting

Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI

Sepsis

China
VarmX B.V.

Recruiting

Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulant

Coagulation Disorder

Netherlands
Zhongming Qiu
The Second Affiliated Hospital of Chongqing Medical University; Mianyang Central... and other collaborators

Not yet recruiting

Tirofiban for Successful Endovascular Stroke Thrombectomy (ADJUVANT-2)

Stroke, Acute Ischemic
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC

Gastric Cancer | Diffuse Type Carcinoma

China
Fudan University

Not yet recruiting

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment (FD-IMPACT)

Pancreatic Cancer

China
Azienda Ospedaliero, Universitaria Ospedali Riuniti

Recruiting

Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population

Intracardiac Thrombus

Italy
Egymedicalpedia

Not yet recruiting

Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients

Plaque Psoriasis

Egypt
Fundacao Champalimaud

Not yet recruiting

Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab (KEYPARTNER)

Triple Negative Breast Cancer | Early Breast Cancer

Portugal
Queen Mary University of London

Not yet recruiting

Thromboprophylaxis in Lower Limb Immobilisation (TiLLI)

Thrombosis | Injury Leg
Mayo Clinic

Recruiting

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer

Prostate Adenocarcinoma | Oligometastatic Prostate Carcinoma

United States
Peking University People's Hospital

Not yet recruiting

Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD

cGVHD
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage... and other conditions
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Sintilimab Plus FOLFIRI as Salvage Therapy for Patients With Advanced Gastric Cancer

Unresectable/Metastatic Gastric Cancer

China
Dana-Farber Cancer Institute
Eli Lilly and Company

Not yet recruiting

ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab

Endometrial Cancer | Recurrent Endometrial Cancer | TP53

United States
ITB-Med LLC

Recruiting

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

Kidney Transplantation

Spain, Sweden, Austria
Al-Azhar University
Sphinx university

Not yet recruiting

The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus (RCT)

Lichen Planus, Oral

Egypt
Octapharma

Not yet recruiting

Phase 3 Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

Acute Hereditary Angio Edema
Peking Union Medical College Hospital
Xiangya Hospital of Central South University; Ruijin Hospital; China-Japan Friendship...

Recruiting

The Study of Monitoring and Dosing Guidance of Direct Oral Anticoagulants Based on Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics

Pulmonary Embolism

China
First Affiliated Hospital of Zhejiang University

Not yet recruiting

A Phase III Study Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL

ETP-ALL

China
Haaglanden Medical Centre
Takeda; Leiden University Medical Center

Not yet recruiting

Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH) (CIAO@SAH)

Subarachnoid Hemorrhage, Aneurysmal
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Not yet recruiting

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States

Search clinical trials for: hypoxia-inducible factor propyl-hydroxylase inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations